Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VO659 in Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease
NCT05822908Phase 2Recruiting
- Sponsor
- Vico Therapeutics
- Start
- Feb 2023
- Primary completion
- Apr 2028
- Countries
- 6
01
Overview
A Phase 2 trial of VO659 in spinocerebellar ataxia type 1 (SCA1), spinocerebellar ataxia type 3 (SCA3), Huntington's disease (HD), sponsored by Vico Therapeutics. Started Feb 2023; status: recruiting.
02
Drugs
VO659
03
Conditions
spinocerebellar ataxia type 1 (SCA1)spinocerebellar ataxia type 3 (SCA3)Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05822908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822908.